The CDKN2 locus expresses two dierent mRNA transcripts, designated a and b. The protein product of the a transcript is the cell cycle inhibitor and tumour suppressor p16INK4a. The b transcript is translated in an alternate reading frame (ARF) and in humans encodes a 15 kDa protein (p19ARF). Immunohistochemical and Western analysis of p16INK4a has shown that the protein is downregulated in a signi®cant number of tumours, but less is known on the expression of the p19ARF. We have examined the expression of p16INK4a and p19ARF in resectable non-small cell lung cancer (NSCLC) by immunostaining (n=49) and multiplex RT ± PCR (n=28). In order to investigate the mechanism responsible for p16INK4a downregulation, exon 1a methylation was analysed in a PCR-based assay. Of 49 tumours examined by immunostaining, 24 and 20 tumours expressed p16INK4a and p19ARF at nil to low levels, respectively. p19ARF was localized primarily to the nuclei of tumour cells, but was also seen to varying degrees in nuclei of lymphocytes, chondrocytes, ®broblasts, and epithelial cells. No tumour with normal p16INK4a had decreased p19ARF expression. Among 16 tumours with nil to low p16INK4a expression, 11 tumours exhibited full methylation of at least one site within exon 1a and these tumours showed normal p19ARF expression. In contrast, no methylation of exon 1a was observed in ®ve tumours which also lacked p19ARF. In normal lung, p16INK4a and p19ARF were not expressed at detectable levels, the multiplex RT ± PCR results were balanced, and sites within exon 1a were strongly methylated. In tumours, imbalanced multiplex RT ± PCR data (p16INK4a5p19ARF) predicted methylation of exon 1a (P=0.0006) as well as downregulation of p16INK4a. p19ARF downregulation was inversely correlated with p53 overexpression (P=0.025), whilst negative immunostaining for p16INK4a was inversely correlated with pRb downregulation (P=0.003) and directly correlated with p53 overexpression as assessed by immunostaining (P=0.015). Our results show that: (1) p16INK4a and p19ARF expression are altered in almost half of resectable NSCLC; (2) methylation within exon 1a is a frequent, but not the only mechanism of p16INK4a downregulation; and that (3) the inverse association of p19ARF and p53 alteration is consistent with a linked pathway.
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Introduction
The CDKN2 gene is located to the short arm of chromosome 9p within a region frequently deleted in malignancy. Analysis of cancer cell lines as well as certain tumour types has revealed a high frequency of homozygous loss as this locus. Mice nullizygous for CDKN2 (exon 2 disrupted, thus both transcripts compromised) rapidly develop spontaneous tumours accelerated by carcinogens. Embryonic ®broblasts derived from these animals fail to senesce in culture and can be easily transformed by oncogenic Ha-ras, implying that the protein products which incorporate CDKN2 exon 2 play a major role in carcinogenesis (Serrano et al., 1996) .
The CDKN2 locus encodes two dierent transcripts derived from alternative splicing of upstream exons (E1a and E1b) to a common splice acceptor site in exon 2 Stone et al., 1995b) . The a transcript encodes the p16INK4a tumour suppressor, while the b transcript gives rise to a completely distinct polypeptide that incorporates exon 2 coding sequences in an alternative reading frame encoding a 15 kDa peptide (Shores et al., 1997; Mao et al., 1995; Stone et al., 1995b) . Thus, while the a transcript encodes p16INK4a, the b transcript encodes an unrelated product (human p19ARF, murine p19ARF). This genetic arrangement is very unusual in mammalian cells (Liggett et al., 1996; Quelle et al., 1995) .
Expression of p16INK4a is abnormal in a large proportion of solid tumours (Kamb et al., 1994; Nobori et al., 1994; Haber, 1997) and germline mutations have been demonstrated in a number of cancer prone families most notably melanoma kindreds. Germline alterations in such families are typically point mutations or small intragenic deletions (Hussussian et al., 1994) . In primary tumours, somatic inactivation of p16INK4a has been reported to occur primarily in pancreatic, and oesophageal cancer, glioblastoma and acute T-cell lymphoblastic leukaemia (Haber, 1997) . In addition, other tumours including head and neck, breast, colon and bladder tumours with apparently normal p16INK4a exons express no p16INK4a. It has been suggested that lack of expression in the face of a normal gene structure can be attributed to de novo methylation, directed against the CpG island that extends from the promoter into exon 1a (Betticher et al., 1997; Gonzalez-Zulueta et al., 1995a; Herman et al., 1995; Merlo et al., 1995) . Several lines of experimental evidence support a tumour suppressor function of p16INK4a: ®rstly, forced overexpression of p16INK4a results in inhibition of phosphorylation of the retinoblastoma protein (pRb), a crucial step in the activation of the cell cycle (Haber, 1997) . The requirement for pRb to eect a p16INK4a cell cycle arrest suggests that p16INK4a and pRb are involved in a common pathway (Betticher et al., 1997; Okamoto et al., 1994; Otterson et al., 1994 Otterson et al., , 1995 Tam et al., 1994; Shapiro et al., 1995; Kelley et al., 1995; Geradts et al., 1995) . Secondly, cultured primary cells express increasing amounts of p16INK4a as they approach the limit of their life-span in vitro (Hara et al., 1996) . Further, forced expression of activated Haras in primary cells induces senescence which can be relieved by inactivation of either p16INK4a or p53 (Serrano et al., 1997) .
The other protein product of the CDKN2 locus, p19ARF, functions also as a growth suppressor. Overexpression of murine p19ARF (homologous to the human p19ARF) induces G1/S and G2/M cell cycle arrest in NIH3T3 ®broblasts (Quelle et al., 1995) . Furthermore, when overexpressed in head and neck and HeLa cervical carcinoma (Liggett et al., 1996) as well as glioma cells (Arap et al., 1997) , p19ARF is able to halt cellular proliferation through a pRb independent pathway. Finally, p19ARF knock-out mice which maintain p16INK4a expression develop carcinogeninduced tumours at an accelerated rate (Kamijo et al., 1997) . Despite the probable importance of ARF proteins in carcinogenesis as suggested by these studies, its mechanism of action has not yet been established. In murine cells, p19ARF function is abolished if cells lack p53 (Kamijo et al., 1997) suggesting an action upstream of p53. In human tumour cells, some point mutations or small deletions, those in exon 1a, exon 3 and some in exon 2 aect p16INK4a function only, while the integrity of p19ARF appears conserved . On the other hand, in the vast majority of cases larger deletions in CDKN2 encompass the coding region of both p16INK4a and p19ARF suggesting that loss of both proteins may favour tumour formation (Stone et al., 1995a) . Similarly, many exon 2 point mutations result in missense or nonsense mutations in both peptides.
In some cases of acute lymphocytic leukaemia, however, p16INK4a sequences were spared while p15INK4b and p19ARF sequences were speci®cally deleted (Heyman et al., 1996) . Likewise, two human melanoma cell lines, A375 and SK-Mel93 sustained localized homozygous deletions of exon 1b while exons 1a, 2 and 3 remained intact allowing expression of p16INK4a transcripts (Stone et al., 1995b) . Although these results are exciting, the frequency of p19ARF expression, at the protein level, in human tissues and tumours and the extent of its role in human carcinogenesis are not yet clear.
We previously reported on a series of resectable nonsmall cell lung carcinoma (NSCLC) examined for defects in genes controlling progression through the G1 phase of the cell cycle. No homozygous loss of CDKN2 was seen in these primaries and point mutations in exons 1a and 2 were rare (6%). Nevertheless, 49% of tumours failed to express detectable p16INK4a. In a subset of selected tumours, we showed that de novo methylation was the likely cause of p16INK4a downregulation. Associating these results with the cyclin D1 and pRb expression status, 92% of resectable NSCLC carried alterations of at least one of these genes which govern progression through the G1 phase of the cell cycle (Betticher et al., 1997) . Our present work examines the expression of p19ARF at the mRNA and protein level in these tumour samples.
Results

Western blot analysis and immunostaining
A polyclonal rabbit antibody was used for the detection of p19ARF in cell lines and NSCLC. The speci®city of this antibody was demonstrated in human osteosarcoma cells (SaOS2) (Shores et al., 1997) . Conversely, the leukaemic cell line K562, with a homozygous CDKN2 loss, served as a negative control: these cells were formalin-®xed and processed in the same manner as the NSCLC specimens and the staining for p19ARF was negative. Western analysis was performed and showed expression of p19ARF in Cos7 transfected cells as well as in HeLa cells. K562 were negative (Figure 1 ). Using the same antibody, immunohistochemistry of normal lung tissue exhibited positivity for p19ARF in lymphocytes, some fibroblasts, chondrocytes and some rare epithelial cells ( Figure 2a ). The staining was low to moderate in intensity and exclusively nuclear. In tumours with p19ARF staining, the protein was localized mainly to the nucleus, but in the majority of cases the cytoplasm was slightly positive ( Figure 2b , Table 1 ). In some tumours (n=6), cytoplasmic exceeded nuclear staining. Forty-one per cent (n=19) of resectable NSCLC were negative for p19ARF nuclear expression. Absent p19ARF expression was not associated with any of the several histopathological features analysed (histological type, grade of dierentiation, amount of necrosis, lymphocytic in®ltration, tumour size, and Figure 1 Immunoblot analysis of p19ARF p16INK4a and p19ARF correlate with p53 in NSCLC S Vonlanthen et al stage of disease). pRb, p16INK4a, cyclin D1, and p53 staining of these tumour samples described elsewhere is summarized in Tables 1 and 2 ( Betticher et al., 1997; Borner et al., 1998) .
Multiplex RT ± PCR
In a subset of tumours (n=28), we examined the expression of p16INK4a and p19ARF by multiplex RT ± PCR. Using speci®c sense primers in exon 1a and exon 1b and a common reverse primer in exon 2, we ampli®ed both transcripts simultaneously in a single reaction. Analysis of ampli®ed products: RT ± PCR of mRNA derived from normal lung tissue from NSCLC patients (n=6) or from a single individual with normal lungs (heart-lung transplantation because of pulmonary hypertension) revealed approximately equal ampli®cation of a and b transcripts under the PCR conditions used. In 16 tumours the relative intensity of a to b ampli®cation products was similar to controls. In all tumours examined, the b transcript could be PCR ampli®ed. The a transcript could not be ampli®ed in 11 out of 28 tumours (Figure 3) . In a further tumour, the size of the p16INK4a transcript was smaller by 15 bp. Sequencing of this product revealed a splice dysfunction in exon 1a at the following site: 5' exon 1-ACCGAATAGTTACG splice to exon 2-3'. Sequencing of the exons and splice junctions ampli®ed from genomic DNA derived from this lesion failed to reveal a mutation that might account for this aberrant splicing event.
This experiment reveals that in some NSCLC the level of b transcript is higher than a. Together with the immunostaining, the NSCLC tumours may be divided into three groups: The ®rst group was characterized by imbalanced a and b transcripts and no p16INK4a staining, whilst p19ARF was strongly expressed. In the case of balanced a and b transcripts as determined by multiplex RT ± PCR, either both proteins were expressed or absent (group 2, positive, group 3, negative, Table 2 ).
Methylation status of exon 1a
In order to investigate further the reason for the downregulation of p16INK4a in group 1, we assessed the methylation status in a series of tumours (n=42). Eleven tumours had at least one site within exon 1a fully methylated (Figure 4) . In all cases where the p16INK4a transcript was not ampli®able in the multiplex RT ± PCR, at least one site in exon 1a was fully methylated (P=0.0006). Furthermore, in all cases where exon 1a was methylated at least at one site, no p16INK4a and p19ARF correlate with p53 in NSCLC S Vonlanthen et al p16INK4a was expressed as assessed by immunostaining (P=0.0002). Interestingly, normal lungs were strongly methylated and had balanced a and b transcripts in multiplex RT ± PCR. This is in accordance with rare positive p16INK4a and p19ARF immunostaining in normal lungs.
Association with pRb, cyclin D1 and p53 (Table 3) Expression of these ®ve proteins assessed by immunostaining was normal in only three tumours (7%). Conversely, 43/46 tumours had at least one protein altered. p16INK4a alterations (lack of expression and mutation) were inversely correlated with pRb expression (P=0.003) and directly correlated with p53 overexpression (P=0.017). On the other hand, p19ARF abnormalities were inversely associated with p53 alterations (P=0.025). Eight out of 46 specimens (17%) had no expression of pRb, whilst p16INK4a, p19ARF and p53 were normal. Conversely, 22/46 of the tumour specimens (48%) had at least two of the genes CDKN2 (p16INK4a/p19ARF) and/or TP53 altered, whilst pRb expression was normal. Thirty-®ve out of 46 tumours analysed (76%) carried a p19ARF and/or p53 alteration. Interestingly, this group of tumours had a higher frequency of p16INK4a downregulation (P=0.0001) and normal pRb expression (P=0.002). No correlation with cyclin D1 overexpression was found (Table 4) .
Discussion
While homozygous loss of CDKN2 is the most frequent cause of p16INK4a downregulation in cancer cell lines, such alterations are infrequent in the majority of solid tumours. De novo methylation of exon 1a, however, has been reported to be another mechanism of p16INK4a silencing (Betticher et al., 1997; GonzalezZulueta et al., 1995a; Herman et al., 1995; Merlo et al., 1995) . Our results on a large number of lung primaries con®rm the frequent association of methylation and p16INK4a downregulation in NSCLC seen commonly in other solid tumours. Eleven out of 42 tumours (26%) had at least one site within exon 1a fully methylated. This was the likely cause for the p16INK4a downregulation. Normal human tissues also exhibited methylation at this locus, as has been demonstrated in colonic mucosa (Gonzalez-Zulueta et al., 1995a) and in this study in normal lung samples. Hypermethylation of the CpG island encompassing exon 1a is therefore con®rmed as the major mechanistic explanation of downregulation in NSCLC, whilst homozygous loss or point mutations occur infrequently (Betticher et al., 1997) . We did not observe any association between methylation of exon 1a in NSCLC and the age of the patients, although an association of age and gene hypermethylation has been described (Issa et al., 1994) . Methylation of CpG islands is generally restricted to genes located on the inactive X chromosome (Singer-Sam and Riggs, 1993) , imprinted genes (Ferguson-Smith et al., 1993) or genes that undergo de novo methylation during dierentiation or cell line immortalization and tumorigenesis (Laird and Jaenisch, 1994) . The results obtained with normal lungs and matched tumour pairs are therefore intriguing. Normal lungs failed to express p16INK4a, presumably as a result of methylation of CDKN2 exon 1a. This result is in contrast with those obtained by Merlo et al. (1995) , probably due to dierent techniques used. However, a sizeable fraction of tumours do express p16INK4a, which we assume is a growth suppressor. Has expression of a negative regulator been induced during tumorigenesis? This explanation would seem unlikely. An alternative explanation is that the origin of lung tumours are stem cells localized in epithelia or in glands. In these Figure 4 Methylation results: normal lung, methylated tumour (group 1), unmethylated tumour (group 3) (groups referring to Table 2 ) . Thus, the analysis of p16INK4a expression and the CDKN2 methylation status of single epithelial or glandular cells might allow the identi®cation of cells out of which lung tumours commonly originate. Using immunostaining we found p19ARF to be downregulated in almost half of resectable NSCLC (41%). The staining was predominantly nuclear, though in the majority of cases concomitant cytoplasmic staining was also present. In six tumours, p19ARF was localized to the cytoplasm. This pattern is in agreement with the staining observed for the p19ARF in mice, where normal cells also exhibited exon 1b expression (Haber, 1997) . In our cases, a few ®broblasts and epithelial cells, in particular those close to the basal membrane had moderate p19ARF expression. Chondrocytes and lymphocytes were also positive and served as internal control. Other cells did not show any p19ARF expression.
Several lines of evidence suggest speci®city of the antibody used in our study: Firstly, bacterially expressed GST-human p19ARF fusion protein is easily recognized by this antibody. Secondly, a weak but speci®c band (13 ± 15 kDa) was immunoprecipitated with p19ARF antibody from a lysate of pRb de®cient human osteosarcoma cells (SaOS2) (Shores et al., 1997) . Thirdly, in our hands K562 cells with homozygous CDKN2 loss were negative for p19ARF expression and ®nally, in this study where strong expression of the p19ARF transcript was demonstrated by RT ± PCR, the tumours were strongly positive for p19ARF staining.
A series of tumours (13/49, 27%) were negative for both p16INK4a and p19ARF staining. Some of these tumours (n=5) were further characterized: they did not exhibit any methylation within exon 1a, or any mutations in exon 1a and exon 2. We were also unable to show homozygous loss at the CDKN2 locus in any case. This raises the possibility that a common mechanism aecting both p16INK4a and p19ARF is altered in some NSCLC. The trivial explanation of poorly processed tumour material can be excluded since staining for other proteins was positive in these tumours (pRb, cyclin D1, bcl-2, mcl-1 and/or p53). p19ARF expression has been recently examined in mouse lung cancer cell lines. Four cell lines did not express p19ARF, a reason for this downregulation could not be identi®ed: no methylation of exon 1b and no deletions or mutations were detected (Swaord et al., 1997) . Loss of transcription factor acting on both promoters (a and b) might conceivably be the cause for simultaneous alterations of p16INK4a and p19ARF. In addition, the possibility of a post-transcriptional regulation of p16INK4a and p19ARF cannot be excluded. Further investigations are needed to shed more light on the regulation of CDKN2 expression.
Little is known about the biological signi®cance of the inactivation of p16INK4a and p19ARF in NSCLC. The inverse correlation of p16INK4a and pRb alteration has been reported several times (Okamoto et al., 1994; Otterson et al., 1994 Otterson et al., , 1995 Tam et al., 1994; Shapiro et al., 1995; Kelley et al., 1995; Geradts et al., 1995) and has also been found in our tumours (P=0.003). Recently, altered expression of p53 has been shown to confer synergistic eects with alterations of the p16INK4a/pRb pathway. As reported in a recent study, p16INK4a and p53 appear to co-operate in tumour growth inhibition (Shapiro et al., 1998) . Combinatorial transfer of p16INK4a and p53 genes by adenoviral vectors in hepatocellular and colon carcinoma cell lines leads to ecient induction of apoptosis, which in pRb-positive tumour cells, could not be achieved by p53 alone (Sandig et al., 1997) . Furthermore, tumours with p16INK4a alterations (point mutations in exon 1a or exon 2) also exhibited p53 point mutation (Marchetti et al., 1997) . Similar data have been reported in human bladder tumours and melanoma cell lines (Gruis et al., 1995) . These results suggest that p16INK4a and p53 products may operate in dierent tumour suppressor pathways, each of which may be important in human carcinogenesis. Our correlation of p16INK4a downregulation with aberrant p53 expression in NSCLC primaries (P=0.017) supports this hypothesis.
Furthermore, the present study on p19ARF reports on a novel and intriguing association with p53 (P=0.025) indicating that p19ARF may be linked with p53 as suggested very recently (Kamijo et al., 1997) . At the time we completed the experiments, two groups independently described a possible function of p19ARF. It potently suppresses oncogenic transformation in primary cells and this function is abrogated when p53 was neutralized by viral oncoproteins, but not by the p53 antagonist mdm-2. This ®nding, coupled with the observation that p19ARF and mdm-2 physically interacts and promotes mdm-2 degradation, is associated with p53 stabilization and accumulation. Thus, alteration of the ARF-INK4a locus simultaneously impairs both the p16INK4a-cyclinD/CDK4-pRb and the p19ARF-mdm-2-p53 pathways (Pomerantz et al., 1998; Zhang et al., 1998) .
Ninety-three per cent of tumours have at least one of the analysed proteins (pRb, p16INK4a, p19ARF or p53) altered. The number of protein alterations may be underestimated, since staining may still detect inactive proteins with intact epitopes (in particular, pRb and p53). Nevertheless, our results reveal that p16INK4a and p19ARF are frequently altered in NSCLC primaries and that they are inversely correlated with pRb (for p16INK4a) and p53 (for p19ARF).
To our knowledge, this is the ®rst report examining p19ARF expression in human tumours. We have shown that p19ARF is downregulated in 41% of NSCLC. Its inverse association with abnormal p53 expression may suggest a common pathway in malignant growth and supports a role for the p19ARF peptide in human cancer.
Materials and methods
Patients characteristics
Tumour samples were obtained from 49 consecutive patients (46 men, three women, median age 64 years p16INK4a and p19ARF correlate with p53 in NSCLC S Vonlanthen et al [45 ± 79] ) who underwent resection of NSCLC at the University Hospital of Bern, Switzerland. They had received no therapy prior to surgery (pneumonectomy [n=14] or (bi-) lobectomy [n=35]). Twenty-six patients were in stage I, four in stage II and 19 in stage III (UICC, 1987) . The histological type of all tumours was determined according to the standard criteria of the WHO (1981) : 32 were squamous cell carcinomas, 10 adenocarcinomas, four undierentiated NSCLC, two large cell carcinomas and one carcinoid.
Cell lines
All cell lines were cultured in a 378C incubator with 5% CO 2 in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% foetal calf serum. The human chronic myeloblastic leukaemia cell line K562 with a homozygous deletion of the INK4a locus was used as a negative control. The Cos7 cells, transfected with p19ARF (produced by WGY, Shores et al., 1997) and the HeLa cells were used as positive controls for immunoblot analysis.
DNA and RNA extraction
DNA and mRNA were isolated from frozen tissue samples. High molecular weight DNA was prepared according to standard protocols (Blin and Staord, 1976) and mRNA was extracted using Dynabeads (Dynal, Oslo, Norway).
Western blot analysis
Cells were lysed in a Nonidet P40 lysis buer (50 mM TrisHCl pH 7.5, 150 mM NaCl, 0.5% v/v NP-40 and protease inhibitors (complete2, Boehringer Mannheim)). Protein concentrations were determined by a modi®ed method of Bradford (Bio-Rad). We used 120 mg and 10 mg of total protein for the analyses of K562/HeLa cells and Cos 7 cells, respectively. Cell lysates were size-fractioned on a 15% SDS ± PAGE and transferred to nitrocellulose (Schleicher & Schuell). The membrane was blocked at 48C overnight in 2.5% dry milk and probed for 2 h with a polyclonal antibody against p19ARF (produced by WGY) diluted 1 : 500. Detection was performed using an enhanced chemiluminescence detection system (ECL, Amersham) according to manufacturer's recommendation.
Immunohistochemistry
The staining for p53, pRb, cyclin D1 and p16INK4a were performed as recently described (Betticher et al., 1997; Borner et al., 1998) . For p19ARF staining, 4 mm formalin®xed, paran-embedded sections were dewaxed, rehydrated, and boiled in 10 mM citrate buer, pH 6.0, in a microwave oven for 2610 min. Sections were then (and following all subsequent steps) washed in Tris-buered saline (TBS), blocked for 5 min with 20% normal goat serum (Dako, Glostrup, Denmark) and thereafter incubated with a 1 : 500 dilution (Dako antibody diluent) of a rabbit polyclonal antibody against p19ARF (produced by WGY) for 60 min at room temperature. One control section was incubated with normal rabbit serum, also diluted 1 : 500 in antibody diluent, for the other control the primary antibody was replaced with buer. Sections were then incubated in a 1 : 100 dilution (in TBS) of biotinylated goat antibody to mouse/rabbit immunoglobulins (Dako) and thereafter with avidin-biotin-complex/horseradish peroxidase (1 : 100 in TBS) (Dako). Finally, sections were developed in 3,3-diaminobenzidine (Sigma FAST DAB tablets), counterstained with haemalaun, and mounted.
A tumour was considered to be negative for both p16INK4a and p19ARF if less than 5% of the tumour cells were positive for nuclear staining. For p16INK4a, very few control cells were positive, thus, a separate positive control was included within every series of tumours stained. For p19ARF staining, lymphocytes in each section were found to express p19ARF at low to moderate levels served as a positive internal control. Slides were assessed blinded and without knowledge of the results of the molecular analyses. Furthermore, controls were performed through repeating the staining of identical sections in dierent batches. Dierent blocks of the same tumour were processed and high consistency was observed in the majority of cases. In a few cases of discordance, staining was repeated to clarify the result.
Multiplex RT ± PCR
To compare relative levels of a and b transcripts we performed multiplex RT ± PCR. Reverse transcription to cDNA was carried out using a Superscript Preampli®cation System (Life Technologies, Paisley, UK). The following primers were used for each reaction, in exon 1a (sense 1) 5'-GCTGCCCAACGCACCGAATA-3' in exon 1b (sense 2) 5'-CCCTCGTGCTGATGCTACTGA-3' and exon 2 (reverse) 5'-ACCACCAGCGTGTCCAGGAA-3'. One mg of cDNA was added to 99 ml of a PCR mixture containing 100 mM of each dNTP, 0.5 mg of each primer, 5% DMSO, 16PCR buer (Boehringer) and 2.5 units of Taq Polymerase (Boehringer). Thirty-®ve cycles were performed in an automated thermocycler with the following hot-start PCR conditions: denaturation temperature of 948C (30 s), annealing of 578C (30 s) and elongation of 748C (30 s). Twenty ml of the products were run on a 3% agarose gel containing ethidium bromide.
PCR based methylation assay
A PCR assay relying on the inability of restriction enzymes to cut methylated sequences was used for the analysis of the methylation status of the exon 1a (Gonzalez-Zulueta et al., 1995b) . One mg of genomic DNA was digested with 10 units of EcoRI, MvnI, KspI, CfoI, and MspI according to the manufacturer's instructions (Boehringer). Eighty ng of digested DNA were ampli®ed with primers¯anking the restriction sites (5'-AGCCTTCGGCTGACTGGCTGG-3' and 5'-CTGGATCGGCCTCCGACCGTA-3'), conditions: 22 cycles, 948C (60 s, ®rst cycle 3 min), 558C (30 s) and 728C (40 s, last cycle, 4 min). PCR products were run on a 1.5% agarose gel, transferred to a nylon membrane and hybridized with a digoxigenin labelled p16INK4a exon 1a speci®c probe. Exon 1a was regarded as methylated when at least one of the three examined sites was fully methylated.
Statistical analyses
Contingency tables were analysed by Fisher's exact test, while the Wilcoxon rank sums test was used for continuous variables. All tests were two sided and the level of signi®cance was 0.05.
